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Abstract
Background—The optimal strategy for monitoring cystic fibrosis (CF) lung disease in infancy
remains unclear.
Objective—To describe longitudinal associations between infant pulmonary function tests
(iPFTs), chest radiograph (CXR) scores and other characteristics.
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Methods—CF patients ≤ 24 months old were enrolled in a 10-center study evaluating iPFTs 4
times over a year. CXRs ~1 year apart were scored with the Wisconsin and Brasfield systems.
Associations of iPFT parameters with clinical characteristics were evaluated with mixed effects
models.
Results—The 100 participants contributed 246 acceptable flow/volume (FEV0.5, FEF75) and 303
acceptable functional residual capacity (FRC) measurements and 171 CXRs. Both Brasfield and
Wisconsin CXR scores worsened significantly over the 1 year interval. Worse Wisconsin CXR
scores and S. aureus were both associated with hyperinflation (significantly increased FRC) but
not with diminished FEV0.5 or FEF75. Parent-reported cough was associated with significantly
diminished FEF75 but not with hyperinflation.
Conclusions—In this infant cohort in whom we previously reported worsening in average lung
function, CXR scores also worsened over a year. The significant associations detected between
both Wisconsin CXR score and S. aureus and hyperinflation, as well as between cough and
diminished flows, reinforce the ability of iPFTs and CXRs to detect early CF lung disease.
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INTRODUCTION
The hallmark features of cystic fibrosis (CF) lung disease include airway infection,
inflammation, obstruction and structural lung damage1-4. These abnormalities begin in
infancy1-7, often prior to the onset of symptoms4, and unrecognized early airway damage
may progress to irreversible bronchiectasis3. Widespread adoption of newborn screening for
CF offers the opportunity to intervene in the pre-symptomatic period in order to improve
outcomes8. Detecting and monitoring early CF lung disease is therefore likely to improve
long-term outcomes, but the optimal strategy for monitoring remains unclear.
Infant pulmonary function test (iPFT) measurements by the raised volume rapid
thoracoabdominal compression technique (RVRTC) have been shown to be associated with
lower airway infection, inflammation and bronchiectasis on computed tomography (CT) of
the chest2,3,6,7,9 and to track into the preschool years10,11. While chest CT is the most
sensitive means of detecting bronchiectasis in infants with CF12, concerns remain regarding
the attendant risks of anesthesia and radiation exposure. Chest radiographs (CXRs) are
recommended in infants as part of routine clinical care13 and are widely employed. The
association of iPFTs and CXR scores in infants has not to our knowledge been evaluated and
little is known about the association of iPFTs and other clinical characteristics such as
respiratory rate, oximetry or cough. The objective of the current study was to describe cross-
sectional and longitudinal associations between iPFTs and clinical characteristics, including
CXR scores, in a multicenter cohort of infants with CF1. Portions of this work have
previously been presented in abstract form14.
METHODS
Overview and study visits
This was a ten-center, longitudinal, observational study of lung function and associated
clinical characteristics in a cohort of infants with CF; details have been previously
published1. Study visits occurred at enrollment, 6 and 12 months, with an additional visit
within a 28 to 35 day window of one of these visits. At each visit, infants participated in
sedated lung function testing and clinical data were collected.
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Inclusion criteria included age ≤24 months at enrollment and confirmed diagnosis of CF15.
Exclusion criteria included: (1) acute intercurrent respiratory infection, defined as an
increase in cough, wheezing, or respiratory rate in the preceding 3 weeks; (2) currently
hospitalized for a pulmonary exacerbation; (3) oxyhemoglobin saturation <90% on room air.
Additional exclusion criteria were related to contraindications to sedation, as previously
published1. IRB approval was obtained at each site and informed consent from the parent/
guardian of each participant.
Pulmonary function testing
After sedation with 75-125 mg/kg of oral or rectal chloral hydrate (maximum 2 g),
plethysmography followed by RVRTC was performed with the nSpire Infant Pulmonary
Lab (IPL, nSpire, Inc, Longmont, CO, USA), as previously described1. All PFT data were
reviewed by an expert panel (SD, RJ, GK) for selection of acceptable measurements16-18 for
analyses. Based on our prior results,1 the measures analyzed for this manuscript were
functional residual capacity (FRC) obtained by plethysmography, forced expiratory volume
at 0.5 seconds (FEV0.5) and forced expiratory flow at 75% of FVC (FEF75), obtained by
RVRTC. Z scores for FRC were derived from the reference equations of Castile, et al18 and
for FEV 0.5 and FEF75 from Jones, et al19.
Clinical evaluation
At each study visit, data were collected on quiet respiratory rate, oximetry, oropharyngeal
cultures, hospitalizations, medications, length, weight and parent-reported cough (0 (none),
1 (rare), 2 (in the morning), 3 (productive cough))20. At enrollment, additional data were
collected on gender, race, birth history, CF genotype, family history of asthma and
environmental allergies, cigarette smoke exposure, and CF diagnosis through newborn
screening. CF genotype functional class was categorized according to the method of
McKone, et al21 and Green et al22: minimal CFTR function: both alleles with mutations in
functional class 1, 2 or 3; residual function: one or both alleles with mutations in CFTR
functional class 4 or 5.
CXRs and Scoring
CXRs were obtained within 90 days of the enrollment and month 12 study visits. They were
scored centrally by a reviewer (PF) with >20 years’ experience in quantitative radiographic
assessment of lung disease, blinded to participant identity, age and date. Posterior-anterior
and lateral radiographs were scored concurrently by the Wisconsin23 and Brasfield24
systems, in batches of 50. Each session began with scoring of six standard calibration films
to maximize inter-session consistency. The scorer entered results onto standardized paper
report forms. Scores were then entered in duplicate into an Access database. In order to
evaluate intra-rater reliability, duplicates of 30 study films were inserted randomly into the
set of films to be scored. The scorer was blinded to the presence of these additional films.
The Wisconsin score was calculated by the additive method23; the possible scores range
from 0 (mildest) to 100 (most severe). Possible Brasfield scores range from 25 (mildest) to 0
(most severe)24.
Statistical Analysis
Participant characteristics were summarized with standard descriptive statistics. Intra-rater
reliability of CXR scores was assessed with the intraclass correlation coefficient. When
more than one CXR score was available for a film, one score was chosen randomly for all
analyses. The correlation between Brasfield and Wisconsin CXR scores at enrollment was
assessed using the Spearman correlation coefficient with the confidence interval determined
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by bootstrap methods. Because cough is a hallmark clinical characteristic of early CF lung
disease16, we evaluated the association of CXR score and parent-reported cough at the
nearest study visit, using generalized linear mixed effects models using a logit link with a
random intercept to account for repeated measures. Based on the Wisconsin Neonatal
Screening Trial we chose a Wisconsin score of 5 and a Brasfield score of 21 to define the
threshold value for transition to potentially irreversible abnormalities16.
Associations of each lung function parameter with clinical characteristics at the same visit
were evaluated using mixed effects models with a random intercept to allow the use of data
from all visits and account for repeated measures. Models were adjusted for age, gender and
length (time-varying). The effect of baseline clinical characteristics on change from baseline
in lung function z-score over the study period was assessed using mixed effects models with
random subject and age effects and an interaction between age and the clinical measure.
Slope estimates for change in CXR scores with age were derived from a mixed effects
model with random intercept. No adjustment was made for multiple comparisons in this
hypothesis-generating study. Analyses were conducted using R statistical package version
2.13 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Participants and data collected
One hundred participants from 10 sites were enrolled between 2003 and 2006. Two hundred
forty six acceptable RVRTC measurements were obtained from 90 participants and 303
acceptable FRC measurements from 96 participants. One hundred seventy one CXRs were
obtained from 98 participants (96 from enrollment, 3 from the 6 month visit and 72 from the
12 month visit). The mean time between CXRs and the corresponding lung function tests
was -9.1 (SD 24.9) days; median time was 0 days.
Enrollment characteristics of the study cohort are displayed in Table 1. The mean (SD) age
at enrollment was 14 (6.2) months. Most participants (78%) had minimal CFTR function
(mutations on both alleles in functional class 1, 2 or 3). Twenty one percent were diagnosed
by newborn screening. Average height and weight percentiles were slightly below the
general population mean. Almost half of parents reported no cough and 11% reported
cigarette smoke exposure in utero or after birth. (Because of the observed distribution of
parent-reported cough, cough was dichotomized as present/absent in all subsequent
analyses.) Mean FEF75 z score at enrollment was mildly reduced (-0.47, SD 1.5) and mean
FRC z score slightly elevated (1.77, SD 2.5). (Lower FEF75 z scores indicate airflow
limitation and higher FRC z scores indicate hyperinflation.) CXR scores were in general in
the mild range, with mean (SD) Brasfield score 22 (1.5) and mean (SD) Wisconsin score 3.5
(2.7).
CXRs
Based on duplicate scoring of 30 radiographs selected at random, the intraclass correlation
coefficient was 0.50 (95% CI 0.17, 0.73) for the Brasfield system and 0.56 (95% CI 0.27,
0.77) for the Wisconsin system. At enrollment, 6 of 96 participants had no abnormalities
detected with the Wisconsin system (score = 0) and the same 6 had no abnormalities
detected with the Brasfield system (score = 25). The correlation between Wisconsin and
Brasfield scores at enrollment was r = -0.75 (95% CI -0.67, -0.81, p<0.001) (Figure 1).
Wisconsin and Brasfield CXR scores both worsened significantly with age during the one
year study period (Figure 2; Wisconsin mean slope per year 0.86, 95% CI 0.31, 1.41,
p=0.005; Brasfield mean slope per year -0.71, 95% CI -1.01, -0.41, p<0.001). Among the
141 CXRs, 40 (23%) had a Wisconsin score ≥5 and 41 (24%) had a Brasfield score <21,
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suggesting a transition to potentially irreversible lung disease16. Twenty five CXRs had both
a Wisconsin score ≥5 and a Brasfield score <21. There was no association between either
score and presence of parent-reported cough: OR 1.62 (95% CI 0.71, 3.67) for Wisconsin
score ≥5 and OR 1.20 (95% CI 0.53, 2.73) for Brasfield score <21. (An OR >1 indicates that
a worse CXR score is associated with the presence of cough.)
Lung function
As previously published1, mean (95% CI) z scores for all acceptable lung function measures
were as follows: FRC 1.92 (1.39, 2.45), FEV0.5 0.06 (-0.15, 0.26), FEF75 -0.52 (-0.78,
-0.25). In addition, FEV0.5 worsened significantly with increasing age (slope -0.6, 95% CI
-0.83, -0.37) and there was a trend towards worse FEF75 and FRC with increasing age1.
Associations of lung function and clinical characteristics
The associations of each clinical characteristic with each lung function parameter at the
same study visit are displayed in Table 2, from mixed effects models. There was a
significant association between Wisconsin CXR score and FRC: a 1 unit higher (worse)
CXR score was associated with a mean 4.62 (95% CI 0.66, 8.59) ml higher (worse) FRC.
There was also a significant association between the isolation of S. aureus from the most
recent respiratory culture and FRC: a culture positive for S. aureus was associated with a
mean 19.3 ml (95% CI 5.1, 33.4) higher FRC. Parent-reported cough was associated with a
mean 34.6 ml/s (95% CI 64.2, 5.1) lower FEF75. None of these clinical characteristics was
associated with both worse hyperinflation (FRC) and airway obstruction (FEV0.5, FEF75).
Significant associations were not detected between any lung function parameter and
cigarette smoke exposure, P. aeruginosa culture status, CF genotype functional class, weight
percentile, Brasfield CXR score, respiratory rate or oximetry.
The effect of baseline P. aeruginosa culture status, baseline weight percentile, CFTR
functional class and cigarette smoke exposure on the change from baseline in lung function
z-scores (FEV0.5, FEF75 and FRC) was assessed by including an interaction between age
and the clinical measure in a mixed effects model with random intercept and slope. No
significant effect of any baseline characteristic on rate of change of any lung function
parameter was detected.
DISCUSSION
In this U.S. multicenter cohort of infants with CF in whom we previously reported a
worsening in average lung function1, we now report that mean Brasfield and Wisconsin
CXR scores also worsen significantly over a one-year interval. We also found that worse
Wisconsin CXR score and S. aureus respiratory infection were significantly associated with
hyperinflation (higher FRC), and that parent-reported cough was significantly associated
with peripheral airway obstruction (lower FEF75). The reason that we did not observe
physiologically consistent effects of these characteristics on both hyperinflation and airway
obstruction is unclear.
Chest CTs have been shown to detect bronchiectasis as early as 3 months of age12, but are
expensive and carry risks associated with radiation and anesthesia. In school age children
and adolescents with CF, Sanders and colleagues recently showed that CXRs were important
predictors of future lung dysfunction, performing as well as CT scans25, and that Wisconsin
and Brasfield CXR scores had excellent sensitivity for detecting abnormal chest CTs26. The
Wisconsin CF Radiograph Scoring System was specifically developed as an alternative to
older scoring systems such as the Brasfield to be sensitive to mild CF lung disease19, though
Rosenfeld et al. Page 5













neither system was developed to detect the very mild abnormalities now generally seen in
infants and toddlers such as those in our cohort.
To our knowledge, ours is the first study to compare Wisconsin and Brasfield CXR scores
specifically in infants, evaluate their changes over time in this age range, and to compare
CXR scores with iPFTs. Both scoring systems were able to detect abnormalities, though not
necessarily in the same participants. Our results do not suggest that one system is superior to
the other in this age range. Intra-rater variability was only fair (ICC = 0.5) for both scoring
systems in the best possible scenario (single, highly trained scorer). In fact, intra-rater
variability for CF-specific CT scoring systems is better (ICC 0.8 – 0.95 in published
studies)27,28. In addition, variability would likely be greater with less experienced or
multiple scorers, reducing the utility of CXR scoring. Our results suggest that, while both
Brasfield and Wisconsin scores may be appropriate scoring systems in infants, with similar
abilities to detect abnormalities, they may be challenging to implement in a manner that
ensures accurate and reproducible results. Of note, both scoring systems evaluate hard-copy
films rather than digitized electronic images. It is possible that adapting the scoring systems
to digital images could improve intra- and inter-rater variability.
Our finding of an association between lung function (FRC) and recent S. aureus infection
complements the recent finding by Pillarisetti, et al2 in a cohort of newborn-screened
Australian infants, that FEV0.5 z scores declined significantly more rapidly in those infected
with S. aureus. Both studies suggest a potential adverse effect of S. aureus on lung function
in infancy. In addition, in the Wisconsin Neonatal Screening Trial, Farrell, et al found an
association between Wisconsin CXR score and the occurrence of two respiratory cultures
positive for S. aureus in the first 2 year of life16. In contrast to Pillarisetti, et al, as well as
our findings in preschool children with CF11,29, we did not detect a significant effect of P.
aeruginosa infection on lung function. This may have been due to the small number of
infants who acquired Pseudomonas in our cohort, as the observed trends in both airway
obstruction (lower FEV0.5 and FEF75) and hyperinflation (higher FRC) were in the
biologically plausible direction. Our finding of an association between cough and peripheral
airway obstruction (FEF75) corroborates that of Kozlowska, et al in the London CF
Collaborative infant cohort as well as our own finding in infant and preschool CF children11.
Strengths of our study include the relatively large size and multicenter nature of our cohort,
improving external validity, as well as rigorous quality control and centralized over-reading
of all infant PFT data and scoring of all CXRs by a single experienced scorer, minimizing
misclassification. Limitations include the short observation period (one year per participant)
and lack of more invasive tests such as CT scans or bronchoalveolar lavage. We relied on
oropharyngeal cultures for respiratory microbiology, which are known to have limited
diagnostic accuracy relative to lower airway cultures30. In addition, because the infants in
our cohort were enrolled at a relatively “mature” age (mean age at enrollment of 14 months),
our results may not be generalizable to newborn infants diagnosed shortly after birth by
newborn screening. Lastly, given the multiple statistical tests performed, some of our results
could be due to chance and should be corroborated in other cohorts.
In conclusion, our results suggest that both infant PFTs and CXRs may be helpful in
monitoring CF lung disease in infants, but also highlight challenges of each of these
modalities. Infant lung function tests (plethysmography and RVRTC) require sedation,
extensive training and expensive equipment and are not strongly associated with clinical
characteristics. Similarly, while CXRs may play a role in detection of early structural airway
damage, the expertise required to perform reliable and accurate scoring currently limits their
utility. Thus, the “holy grail” of CF infant lung disease monitoring remains elusive. The lung
clearance index measured by multiple breath washout holds promise as a sensitive and non-
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invasive measure of early heterogeneity of ventilation4,31-33, but conditions for testing in
infants are still undergoing validation and it may not be more sensitive than RVRTC in
infants4,34. In the future, chest MRI may be used to evaluate aspects of both structure and
function without the radiation risks associated with CT, but is still undergoing validation35.
In fact, monitoring of lung health in infants with CF will likely always require multiple
modalities that provide complementary information on lung structure, function and infection
and inflammation status. Currently, the risk:benefit ratio of more invasive and more accurate
tools such as CT scans, bronchoalveolar lavage and sedated infant PFTs and less invasive
but less accurate tools such as CXRs and oropharyngeal cultures must be weighed on an
individual basis.
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Figure 1. Correlation between Wisconsin and Brasfield chest radiograph scores at enrollment
Wisconsin scores can range from 0 (mildest) to 100 (most severe), and Brasfield scores from
25 (mildest) to 0 (most severe). Brasfield scores are jittered to allow for visibility of all data
points.
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Figure 2. Longitudinal CXR scores by age
Grey dotted lines connect measures within the same subject. Solid line represents the
estimated average trend in CXR score with age (slope and 95% CI).
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Table 1
Characteristics of the Participants at Enrollment
N n (%) or Mean (SD)
Male 100 55 (55)
Age, mo 100 14 (6.2)




Pancreatic insufficient2 100 93 (93)
Diagnosis by newborn screening3 100 21 (21)
Height percentile 100 32.7 (26.4)
Weight percentile 100 27.7 (26.3)
P. aeruginosa positive4 99 12 (12)




In morning 6 (6)
Productive 1 (1)
Cigarette smoke exposure6 100 11 (11)
FEF75 79
ml/s 321 (124)
z score -0.47 (1.5)
FEV0.5 79
ml 330 (92)
Z score 0.10 (1.3)
FRC 93
ml 258 (84)
Z score 1.77 (2.5)
Brasfield CXR Score7 96 22 (1.5)
Wisconsin CXR Score8 96 3.5 (2.7)
1
Minimal, both CFTR mutations in functional class 1, 2 or 3. Residual, one or both mutations in functional class 4 or 517, 18
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2
Reported use of pancreatic enzyme replacement therapy
3
Newborn screening for CF was being performed at only two of the participating centers at the time of study enrollment, the University of
Colorado and Children’s Hospital Boston
4
Based on enrollment oropharyngeal culture
5
As per reference 20
6
Mother smoked during pregnancy or child exposed to smoke after birth, by parent report
7
Scores can range from 0 to 25. A higher score indicates milder disease.
8
Scores can range from 0 to 100. A higher score indicates more severe disease.
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